<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00408993</url>
  </required_header>
  <id_info>
    <org_study_id>10599</org_study_id>
    <secondary_id>F1J-MC-HMEQ(a)</secondary_id>
    <nct_id>NCT00408993</nct_id>
  </id_info>
  <brief_title>Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China</brief_title>
  <official_title>Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      To determine if duloxetine 60mg up to 120mg daily can work in treating pain from Diabetic
      Neuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Brief Pain Inventory (BPI) Worst Pain, Least Pain, and Current Pain Severity and Average Interference Scores</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Measures severity of pain and interference of pain on function. Each severity of pain (worst, least, and current) scores range from 0 (no pain) to 10 (pain as severe as you can imagine). The 7 separate Interference item scores range from 0 (does not interfere) to 10 (completely interferes) and were averaged to provide a single score (0 to 10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Clinical Global Impression of Severity</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course of Change in Patient Global Impression - Improvement Scale</measure>
    <time_frame>baseline, over 12 weeks</time_frame>
    <description>A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in EuroQoL Questionnaire - 5 Dimensions (EQ-5D) (US Based Index Score)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The EQ-5D is an assessment of one's overall health. Consists of 5 items. Patients choose 1 of 3 options that best describe the status of each item. The EQ-5D US based index scores range from -0.11 to 1.0 where a score of 1.0 indicates perfect health. A positive change from baseline indicates health improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Discontinuing Due to Adverse Events</measure>
    <time_frame>over 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events Reported in &gt;5% of Either Treatment Group by Time of Dosing (Morning or Evening)</measure>
    <time_frame>over 12 weeks</time_frame>
    <description>Tolerability of morning versus evening dosing, as assessed by the number of participants with spontaneously reported adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Athens Insomnia Scale 8-item and 5-item</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Estimates sleep difficulty. Consists of 8 items rated on a 4-point scale of 0 (no problem at all) to 3 (very serious problem). Total score of the 8-item version (sum of items 1-8) ranges from 0-24, while total score of the 5-item (sum of items 1-5) ranges from 0-15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Weight</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline to endpoint in body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Pulse Rate</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline to endpoint in pulse rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Blood Pressure</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline to endpoint in systolic and diastolic blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Change From Baseline to 12 Week Endpoint in Laboratory Measures - Chloride, High Density Lipoprotein, Sodium, and Triglycerides</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Significantly different laboratory values between the two groups in baseline to endpoint changes in chloride, high density lipoprotein, sodium, and triglycerides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically Significant Change From Baseline to 12 Week Endpoint in Laboratory Measures - Uric Acid</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Significantly different laboratory values between the two groups in baseline to endpoint changes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine Hydrochloride</intervention_name>
    <description>60 mg every day (QD) (morning or evening), by mouth (PO)</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>LY248686</other_name>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo every day (QD), by mouth (PO)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have pain due to bilateral peripheral neuropathy caused by Type I or Type II diabetes
             with the pain beginning in the feet and present for at least 6 months.

          -  May not be pregnant and agree to utilize medically acceptable and reliable means of
             birth control during participation in the study.

          -  Score of 4 or greater on the Brief Pain Inventory on the 24-hour average pain item.

        Exclusion Criteria:

          -  Glycosylated hemoglobin (A1C) &gt; 12%

          -  Severe hepatic disease

          -  History of substance abuse or dependence within the past year, excluding nicotine and
             caffeine.

          -  Serious or unstable cardiovascular, hepatic (acute liver injury such as hepatitis or
             severe cirrhosis), kidney, respiratory, blood disorder, seizure disorder, problems
             with peripheral vascular disease, or other medical conditions or psychiatric
             conditions that would hinder your participation or likely to lead to hospitalization
             during the course of the study.

          -  Taking monoamine oxidase inhibitor (MAOI) within 14 days of starting the study or the
             potential need to take during or within 5 days after discontinuation from the study.

          -  Treatment of fluoxetine within 30 days of starting the study.

          -  Unstable blood sugar control and uncontrolled or poorly controlled hypertension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri from 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100101</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changsha</city>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Harbin</city>
        <zip>150086</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nanjing</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nanjin</city>
        <zip>210012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shanghai</city>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wu Han</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Gao Y, Ning G, Jia WP, Zhou ZG, Xu ZR, Liu ZM, Liu C, Ma JH, Li Q, Cheng LL, Wen CY, Zhang SY, Zhang Q, Desaiah D, Skljarevski V. Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China. Chin Med J (Engl). 2010 Nov;123(22):3184-92.</citation>
    <PMID>21163113</PMID>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2006</study_first_submitted>
  <study_first_submitted_qc>December 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2006</study_first_posted>
  <results_first_submitted>February 5, 2009</results_first_submitted>
  <results_first_submitted_qc>April 9, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2009</results_first_posted>
  <last_update_submitted>July 22, 2011</last_update_submitted>
  <last_update_submitted_qc>July 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Duloxetine</title>
          <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Duloxetine</title>
          <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="106"/>
            <count group_id="B2" value="109"/>
            <count group_id="B3" value="215"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.59" spread="10.37"/>
                    <measurement group_id="B2" value="59.90" spread="9.52"/>
                    <measurement group_id="B3" value="59.25" spread="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Major Depressive Disorder</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Diabetes Mellitus</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type I Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type II Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beck Depression Inventory-II Total Score</title>
          <description>A 21-item, patient-completed questionnaire to assess characteristics of depression. Each of the 21 items corresponding to a symptom of depression is summed to give a single score. There is a four-point scale for each item ranging from 0 to 3. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.97" spread="10.66"/>
                    <measurement group_id="B2" value="15.27" spread="11.49"/>
                    <measurement group_id="B3" value="15.61" spread="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brief Pain Inventory 24-Hour Average Pain Score</title>
          <description>A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.47" spread="1.31"/>
                    <measurement group_id="B2" value="5.52" spread="1.39"/>
                    <measurement group_id="B3" value="5.50" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impressions of Severity Score</title>
          <description>Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.26" spread="0.76"/>
                    <measurement group_id="B2" value="4.38" spread="0.91"/>
                    <measurement group_id="B3" value="4.32" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic Neuropathy History</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Duration of Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.07" spread="6.32"/>
                    <measurement group_id="B2" value="10.21" spread="6.91"/>
                    <measurement group_id="B3" value="9.65" spread="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of Diabetic Neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.13" spread="2.60"/>
                    <measurement group_id="B2" value="2.50" spread="2.98"/>
                    <measurement group_id="B3" value="2.32" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of Diabetic Peripheral Neuropathic Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.09" spread="3.11"/>
                    <measurement group_id="B2" value="3.34" spread="3.36"/>
                    <measurement group_id="B3" value="3.22" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162.64" spread="7.72"/>
                    <measurement group_id="B2" value="162.12" spread="7.96"/>
                    <measurement group_id="B3" value="162.37" spread="7.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Michigan Neuropathy Screening Instrument</title>
          <description>Assesses degree of neuropathy. Responses to 13 out of 15 items are added to obtain total score. Responses of “yes” to items 1,2,3,5,6,8,9,11,12,14,15 are each counted as one point. A “no” response on items 7 and 13 counts as 1 point. Items 4 and 10 are not included in scoring. Total scores range from 0 (no neuropathy) to 13 (severe neuropathy).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.45" spread="1.19"/>
                    <measurement group_id="B2" value="4.59" spread="1.19"/>
                    <measurement group_id="B3" value="4.52" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.06" spread="10.62"/>
                    <measurement group_id="B2" value="63.25" spread="11.52"/>
                    <measurement group_id="B3" value="63.65" spread="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score</title>
        <description>A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Intention to Treat analysis. Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score</title>
          <description>A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).</description>
          <population>Intention to Treat analysis. Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.69" spread="0.19"/>
                    <measurement group_id="O2" value="-2.31" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>With 104 patients per arm, the study has at least 85% power to detect a treatment group difference of -1.20 points in baseline to endpoint mean change on the BPI 24-hour average pain score between Duloxetine and Placebo. Sample size determined using a two-sided t-test with alpha=0.05, and assuming a common standard deviation of 2.5 and a discontinuation rate of 25%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.617</p_value>
            <p_value_desc>Treatment effects were evaluated based on a two-sided significance level of 0.05 and interaction effects at 0.10. No adjustments for multiple comparisons were made.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model=Treatment, Pooled Investigator and Baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Brief Pain Inventory (BPI) Worst Pain, Least Pain, and Current Pain Severity and Average Interference Scores</title>
        <description>Measures severity of pain and interference of pain on function. Each severity of pain (worst, least, and current) scores range from 0 (no pain) to 10 (pain as severe as you can imagine). The 7 separate Interference item scores range from 0 (does not interfere) to 10 (completely interferes) and were averaged to provide a single score (0 to 10).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Intention to Treat analysis. Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Brief Pain Inventory (BPI) Worst Pain, Least Pain, and Current Pain Severity and Average Interference Scores</title>
          <description>Measures severity of pain and interference of pain on function. Each severity of pain (worst, least, and current) scores range from 0 (no pain) to 10 (pain as severe as you can imagine). The 7 separate Interference item scores range from 0 (does not interfere) to 10 (completely interferes) and were averaged to provide a single score (0 to 10).</description>
          <population>Intention to Treat analysis. Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Worst Pain Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.48" spread="0.27"/>
                    <measurement group_id="O2" value="-2.93" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Least Pain Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" spread="0.20"/>
                    <measurement group_id="O2" value="-1.37" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Right Now Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.72" spread="0.26"/>
                    <measurement group_id="O2" value="-1.99" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Interference Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="0.21"/>
                    <measurement group_id="O2" value="-1.88" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <p_value_desc>P-value for Worst Pain Score</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model=Treatment, Pooled Investigator, Baseline and Major Depressive Disorder status at baseline.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.151</p_value>
            <p_value_desc>P-value for Least Pain Score</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model=Treatment, Pooled Investigator, Baseline and Major Depressive Disorder status at baseline.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>P-value for Pain Right Now Score</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model=Treatment, Pooled Investigator, Baseline and Major Depressive Disorder status at baseline.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.077</p_value>
            <p_value_desc>P-value for Average Interference Score</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model=Treatment, Pooled Investigator, Baseline and Major Depressive Disorder status at baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Clinical Global Impression of Severity</title>
        <description>Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Intention to Treat analysis. Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Clinical Global Impression of Severity</title>
          <description>Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients.</description>
          <population>Intention to Treat analysis. Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="0.11"/>
                    <measurement group_id="O2" value="-0.99" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>ANCOVA</method>
            <method_desc>Model=Treatment, Pooled Investigator, Baseline and Major Depressive Disorder status at baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course of Change in Patient Global Impression - Improvement Scale</title>
        <description>A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
        <time_frame>baseline, over 12 weeks</time_frame>
        <population>Intention to Treat analysis. Number of randomized patients with at least one non-missing post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time Course of Change in Patient Global Impression - Improvement Scale</title>
          <description>A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).</description>
          <population>Intention to Treat analysis. Number of randomized patients with at least one non-missing post-baseline data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (N=5, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="0.56"/>
                    <measurement group_id="O2" value="3.51" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (N=98, N=107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="0.09"/>
                    <measurement group_id="O2" value="3.23" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=94, N=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="0.10"/>
                    <measurement group_id="O2" value="2.83" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (N=91, N=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="0.11"/>
                    <measurement group_id="O2" value="2.76" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (N=87, N=92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" spread="0.11"/>
                    <measurement group_id="O2" value="2.58" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.955</p_value>
            <p_value_desc>P-value for Visit 3</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated Measures: Model=Treatment, Pooled Investigator, Visit, Baseline, baseline MDD status, Treatment*Visit and Baseline*Visit.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value for Visit 4</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated Measures: Model=Treatment, Pooled Investigator, Visit, Baseline, baseline MDD status, Treatment*Visit and Baseline*Visit.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <p_value_desc>P-value for Visit 5</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated Measures: Model=Treatment, Pooled Investigator, Visit, Baseline, baseline MDD status, Treatment*Visit and Baseline*Visit.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Visit 6</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated Measures: Model=Treatment, Pooled Investigator, Visit, Baseline, baseline MDD status, Treatment*Visit and Baseline*Visit.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>P-value for Visit 7</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated Measures: Model=Treatment, Pooled Investigator, Visit, Baseline, baseline MDD status, Treatment*Visit and Baseline*Visit.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in EuroQoL Questionnaire – 5 Dimensions (EQ-5D) (US Based Index Score)</title>
        <description>The EQ-5D is an assessment of one's overall health. Consists of 5 items. Patients choose 1 of 3 options that best describe the status of each item. The EQ-5D US based index scores range from -0.11 to 1.0 where a score of 1.0 indicates perfect health. A positive change from baseline indicates health improvement.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Intention to Treat analysis. Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in EuroQoL Questionnaire – 5 Dimensions (EQ-5D) (US Based Index Score)</title>
          <description>The EQ-5D is an assessment of one's overall health. Consists of 5 items. Patients choose 1 of 3 options that best describe the status of each item. The EQ-5D US based index scores range from -0.11 to 1.0 where a score of 1.0 indicates perfect health. A positive change from baseline indicates health improvement.</description>
          <population>Intention to Treat analysis. Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.02"/>
                    <measurement group_id="O2" value="0.10" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.207</p_value>
            <method>ANCOVA</method>
            <method_desc>Model=Treatment, Pooled Investigator, Baseline and Major Depressive Disorder status at baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Discontinuing Due to Adverse Events</title>
        <time_frame>over 12 weeks</time_frame>
        <population>Intention to Treat Analysis. All randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing Due to Adverse Events</title>
          <population>Intention to Treat Analysis. All randomized patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events Reported in &gt;5% of Either Treatment Group by Time of Dosing (Morning or Evening)</title>
        <description>Tolerability of morning versus evening dosing, as assessed by the number of participants with spontaneously reported adverse events.</description>
        <time_frame>over 12 weeks</time_frame>
        <population>Number of randomized patients in each treatment arm for each dosing group</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine - Morning Dosing</title>
            <description>60 mg QD (morning or evening), PO for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine - Evening Dosing</title>
            <description>60 mg QD (morning or evening), PO for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Morning Dosing</title>
            <description>Placebo QD, PO for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Evening Dosing</title>
            <description>Placebo QD, PO for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events Reported in &gt;5% of Either Treatment Group by Time of Dosing (Morning or Evening)</title>
          <description>Tolerability of morning versus evening dosing, as assessed by the number of participants with spontaneously reported adverse events.</description>
          <population>Number of randomized patients in each treatment arm for each dosing group</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdominal discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal distension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain upper</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dry mouth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyslipidaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysuria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperhidrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lethargy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palpitations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomach discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapeutic response unexpected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thirst</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Athens Insomnia Scale 8-item and 5-item</title>
        <description>Estimates sleep difficulty. Consists of 8 items rated on a 4-point scale of 0 (no problem at all) to 3 (very serious problem). Total score of the 8-item version (sum of items 1-8) ranges from 0-24, while total score of the 5-item (sum of items 1-5) ranges from 0-15.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Intention to Treat analysis. Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Athens Insomnia Scale 8-item and 5-item</title>
          <description>Estimates sleep difficulty. Consists of 8 items rated on a 4-point scale of 0 (no problem at all) to 3 (very serious problem). Total score of the 8-item version (sum of items 1-8) ranges from 0-24, while total score of the 5-item (sum of items 1-5) ranges from 0-15.</description>
          <population>Intention to Treat analysis. Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5-Item Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" spread="0.31"/>
                    <measurement group_id="O2" value="-1.97" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-Item Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.58" spread="0.47"/>
                    <measurement group_id="O2" value="-3.31" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.364</p_value>
            <p_value_desc>P-value for 5-Item Score</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model=Treatment, Pooled Investigator, Baseline and Major Depressive Disorder status at baseline.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.590</p_value>
            <p_value_desc>P-value for 8-Item Score</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model=Treatment, Pooled Investigator, Baseline and Major Depressive Disorder status at baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Weight</title>
        <description>Change from baseline to endpoint in body weight.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Weight</title>
          <description>Change from baseline to endpoint in body weight.</description>
          <population>Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
          <units>kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.21"/>
                    <measurement group_id="O2" value="-0.03" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.620</p_value>
            <method>ANOVA</method>
            <method_desc>Model=Treatment and Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Pulse Rate</title>
        <description>Change from baseline to endpoint in pulse rate.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Pulse Rate</title>
          <description>Change from baseline to endpoint in pulse rate.</description>
          <population>Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
          <units>beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="1.06"/>
                    <measurement group_id="O2" value="0.32" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.324</p_value>
            <method>ANOVA</method>
            <method_desc>Model=Treatment and Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Blood Pressure</title>
        <description>Change from baseline to endpoint in systolic and diastolic blood pressure.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Blood Pressure</title>
          <description>Change from baseline to endpoint in systolic and diastolic blood pressure.</description>
          <population>Number of randomized patients with a baseline and at least one non-missing post-baseline value.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="1.61"/>
                    <measurement group_id="O2" value="-1.47" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.95"/>
                    <measurement group_id="O2" value="-0.21" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.642</p_value>
            <p_value_desc>P-value for Systolic Blood Pressure</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model=Treatment and Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.601</p_value>
            <p_value_desc>P-value for Diastolic Blood Pressure</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Model=Treatment and Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Change From Baseline to 12 Week Endpoint in Laboratory Measures - Chloride, High Density Lipoprotein, Sodium, and Triglycerides</title>
        <description>Significantly different laboratory values between the two groups in baseline to endpoint changes in chloride, high density lipoprotein, sodium, and triglycerides.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Number of randomized patients with a baseline and at least one non-missing post-baseline value, based on first values at scheduled visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Change From Baseline to 12 Week Endpoint in Laboratory Measures - Chloride, High Density Lipoprotein, Sodium, and Triglycerides</title>
          <description>Significantly different laboratory values between the two groups in baseline to endpoint changes in chloride, high density lipoprotein, sodium, and triglycerides.</description>
          <population>Number of randomized patients with a baseline and at least one non-missing post-baseline value, based on first values at scheduled visits.</population>
          <units>millimole/Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chloride Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.94" spread="3.07"/>
                    <measurement group_id="O2" value="102.87" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="3.60"/>
                    <measurement group_id="O2" value="-0.20" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Density Lipoprotein Cholesterol Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.37"/>
                    <measurement group_id="O2" value="1.33" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Density Lipoprotein Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.22"/>
                    <measurement group_id="O2" value="-0.04" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.03" spread="2.83"/>
                    <measurement group_id="O2" value="142.76" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="3.64"/>
                    <measurement group_id="O2" value="-0.19" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="1.48"/>
                    <measurement group_id="O2" value="1.40" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="1.07"/>
                    <measurement group_id="O2" value="0.26" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>P-value for Chloride</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Sums of squares from ANOVA on the ranks: Model=Treatment and Pooled Investigator for treatment effects p-value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>P-value for High Density Lipoprotein Cholesterol</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Sums of squares from ANOVA on the ranks: Model=Treatment and Pooled Investigator for treatment effects p-value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>P-value for Sodium</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Sums of squares from ANOVA on the ranks: Model=Treatment and Pooled Investigator for treatment effects p-value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <p_value_desc>P-value for triglycerides</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Sums of squares from ANOVA on the ranks: Model=Treatment and Pooled Investigator for treatment effects p-value.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistically Significant Change From Baseline to 12 Week Endpoint in Laboratory Measures - Uric Acid</title>
        <description>Significantly different laboratory values between the two groups in baseline to endpoint changes</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Number of randomized patients with a baseline and at least one non-missing post-baseline value, based on first values at scheduled visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo every day (QD), by mouth (PO) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Statistically Significant Change From Baseline to 12 Week Endpoint in Laboratory Measures - Uric Acid</title>
          <description>Significantly different laboratory values between the two groups in baseline to endpoint changes</description>
          <population>Number of randomized patients with a baseline and at least one non-missing post-baseline value, based on first values at scheduled visits.</population>
          <units>micromole/Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Uric Acid Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.24" spread="72.51"/>
                    <measurement group_id="O2" value="283.98" spread="75.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Change to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.46" spread="62.19"/>
                    <measurement group_id="O2" value="2.49" spread="53.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANOVA</method>
            <method_desc>Sums of squares from ANOVA on the ranks: Model=Treatment and Pooled Investigator for treatment effects p-values.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>Duloxetine 60/120 mg QD</title>
          <description>Duloxetine 60/120 mg QD</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2"/>
                <counts group_id="E2" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77"/>
                <counts group_id="E2" subjects_affected="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E2" events="33" subjects_affected="31" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Therapeutic response unexpected</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>1-800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

